News

Potential Nitric Oxide Treatment for Resistant Bacterial Infections Gets Patent, May Start Clinical Testing

A possible inhalable treatment for antibiotic-resistant bacterial infections in people with cystic fibrosis due to Pseudomonas aeruginosa now has a U.S. patent and is being readied for a first clinical trial, Novoclem Therapeutics announced. The patent (No. 9,850,322) was issued to the University of North Carolina (UNC) at Chapel Hill where the…

US and Europe’s Top CF Advocacy Groups Endorse Proteostasis’ Triple-combo Trial Plan

The most influential cystic fibrosis advocacy groups in the United States and Europe have endorsed the idea of a Phase 1 clinical trial to test a triple-combo therapy that Proteostasis Therapeutics has developed, the company announced. Proteostatis said the endorsements came from the Cystic Fibrosis Foundation’s and European CF Society’s clinical…

Top 10 Cystic Fibrosis Articles of 2017

A number of cystic fibrosis discoveries, therapy advances and other developments were reported by Cystic Fibrosis News Today during 2017. Now that the year is over, it’s time to review the articles that appealed most to our readers. Here are the 10 most-read articles of 2017, with a brief description of what…

Synthetic Peptide Might Be Potential Treatment for Bacterial Infection Often Seen in CF Patients

Pseudomonas aeruginosa is a bacteria that commonly infects cystic fibrosis patients. Now, researchers have designed a synthetic peptide that blocks the ability of these bacteria to cause disease. This discovery might be crucial in fighting infectious diseases and preventing bacteria from becoming resistant to nearly all the antibiotic drug options available.